Literature DB >> 28820038

Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Patients With Stroke.

Teresa A Allison1, Stephanie Bowman1, Brian Gulbis1, Heather Hartman1, Sara Schepcoff1, Kiwon Lee2.   

Abstract

OBJECTIVE: The aim of this study was to determine whether clevidipine (CLEV) achieved faster blood pressure control compared to nicardipine (NIC) in patients presenting with either an acute ischemic stroke (AIS) or a spontaneous intracerebral hemorrhage (ICH).
METHODS: This was a retrospective, observational, cohort study conducted in patients with AIS or ICH admitted to the emergency department of a Comprehensive Stroke Center from November 2011 to June 2013 who received CLEV or NIC continuous infusion for acute blood pressure management.
RESULTS: The study included 210 patients: 70 in the CLEV group and 140 in the NIC group. There was no difference in mean time (standard deviation [SD]) from initiation of the infusion to goal systolic blood pressure (SBP), CLEV: 50 (83) minutes versus NIC: 74 (103) minutes, P = .101. Comparison of the 2 agents within diagnosis showed no difference. Hypotension developed in 5 (7.1%) CLEV patients versus 14 (10%) NIC patients (P = .003). There was no difference in the percentage change at 2 hours; CLEV: -20% (16%) versus NIC: -16% (16%), P = .058. Mean (SD) time to alteplase administration from admission was 56 (22) minutes in the CLEV group versus 59 (25) minutes in the NIC group (P = .684).
CONCLUSIONS: There was no difference in the mean time from initiation of the infusion to the SBP goal between agents or in the secondary outcomes. Due to the lack of differences observed, each agent should be considered based on the patient care needs of the institution.

Entities:  

Keywords:  acute ischemic stroke; antihypertensive; clevidipine; hypertension; intracerebral hemorrhage; nicardipine

Mesh:

Substances:

Year:  2017        PMID: 28820038     DOI: 10.1177/0885066617724340

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  4 in total

1.  Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Hemorrhagic Stroke.

Authors:  Sara Saldana; James Breslin; Jennifer Hanify; Theodore Heierman; Kristina Larizadeh; Michael Sanchez; William Phipps
Journal:  Neurocrit Care       Date:  2021-12-13       Impact factor: 3.210

Review 2.  The Current Role of Clevidipine in the Management of Hypertension.

Authors:  Bo Xu; Zhen Chen; Gaorui Tang
Journal:  Am J Cardiovasc Drugs       Date:  2021-09-02       Impact factor: 3.571

Review 3.  Hypertensive Crisis in Acute Cerebrovascular Diseases Presenting at the Emergency Department: A Narrative Review.

Authors:  Mariagiovanna Cantone; Giuseppe Lanza; Valentina Puglisi; Luisa Vinciguerra; Jaime Mandelli; Francesco Fisicaro; Manuela Pennisi; Rita Bella; Rosella Ciurleo; Alessia Bramanti
Journal:  Brain Sci       Date:  2021-01-07

4.  Clevidipine use after first-line treatment failure for perioperative hypertension in neurosurgical patients: A single-center experience.

Authors:  Jaume Borrell-Vega; Alberto A Uribe; Marilly Palettas; Sergio D Bergese
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.